Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line

Abstract

Three human leucine-rich repeats and immunoglobulin-like domains (LRIG) genes and proteins, named LRIG1-3, has been previously characterized and it was proposed that they may act as suppressors of tumor growth. The LRIG1 protein can inhibit the growth of tumors of glial cells and the down-regulation of the LRIG1 gene may be involved in the development and progression of the tumor. Real-time reverse transcription-polymerase chain reaction (RT-PCR) is a recently developed technique for quantitative assessment of specific RNA levels. In the current study, it was demonstrated that LRIG1-3 and EGFR mRNA was detected in human pituitary adenoma cell lines and a normal pituitary sample, with differences in the expression levels. Compared to the normal pituitary samples, the expression of LRIG1-3 in HP75 cell line was lower, but the expression of EGFR in HP75 cell line was higher. The results are consistent with LRIG1-3 being tumour suppressor genes, and LRIG genes decreasing the expression of EGFR. The ratio of EGFR/LRIG1 was increased at least 13-fold in HP75 cells compared with the normal pituitary cells, which was also the case for the ratio of EGFR/LRIG2 (14-fold increase in HP75) and EGFR/LRIG3 (11-fold increase in HP75). Further studies were needed to elucidate the explicit role of LRIG genes as negative regulators of oncogenesis in human pituitary adenoma.

Keywords

LRIG / pituitary gland / adenoma / EGFR

References

[1] OnguruO., ScheithauerB. W., KovacsK., et al.. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol, 2004, 17: 772-780

[2] TheodoropoulouM., ArzbergerT., GrueblerY., et al.. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol, 2004, 183: 385-394

[3] GuoD., HolmlundC., HenrikssonR., et al.. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics, 2004, 84: 157-165

[4] HedmanH., NilssonJ., GuoD., et al.. Is LRIG1 a tumor suppressor gene at chromosome 3p14.3?. Acta Oncol, 2002, 41: 352-354

[5] GurG., RubinC., KatzM., et al.. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J, 2004, 23: 3270-3281

[6] GuoD., NilssonJ., HaapasaloH., et al.. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol (Berl), 2006, 111: 238-246

[7] GhiglioneC., AmundadottirL., AndresdottirM., et al.. Mechanism of inhibition of the Drosophila and mammalian EGF receptors by the transmembrane protein Kekkon 1. Development, 2003, 130: 4483-4493

[8] NilssonJ., VallboC., GuoD., et al.. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun, 2001, 284: 1155-1161

[9] HolmlundC., NilssonJ., GuoD., et al.. Characterization and tissue-specific expression of human LRIG2. Gene, 2004, 332: 35-43

[10] SuzukiY., MiuraH., TanemuraA., et al.. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett, 2002, 521: 67-71

[11] ThomassonM., HedmanH., GuoD., et al.. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br J Cancer, 2003, 89: 1285-1289